<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647217</url>
  </required_header>
  <id_info>
    <org_study_id>P012-01</org_study_id>
    <secondary_id>2R44EY019586-02</secondary_id>
    <nct_id>NCT01647217</nct_id>
  </id_info>
  <brief_title>Demodex Blepharitis Treatment Study</brief_title>
  <acronym>DBTS</acronym>
  <official_title>Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tissue Tech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tissue Tech Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol
      (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis
      (reducing ocular demodex counts and achieving the clinical improvement with minimal or no
      irritation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demodex blepharitis is one of the most common causes of chronic blepharitis. The
      investigators preliminary clinical study showed that lid scrub with TTO was effective in
      resolving chronic blepharoconjunctivitis; however, it was not convenient for
      self-administration and caused irritation in some patients. Preclinical safety studies have
      verified that T4O is less irritant. In this study, the investigators will determine the
      optimal regimen of T4O Pads.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Number of Demodex Mites</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in mites count after treatment compared to the baseline data. If the mites' count remains zero during the last two visits, it is considered &quot;complete eradication&quot;. Patients without achieving complete eradication will be categorized as &quot;incomplete eradication&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lid Margin Redness and Bulbar Conjunctival Hyperemia</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Lid margin redness and bulbar conjunctival hyperemia were each assessed using an ordered categorical value ranging from 0 (None) to 3 (Severe). The two scores were summed to obtain the final score, which ranges from 0 (None) to 6 (Severe).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Chronic Blepharitis</condition>
  <arm_group>
    <arm_group_label>Terpinen-4-ol Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placepo Pads Contol Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terpinen-4-ol</intervention_name>
    <description>Lid scrub once or twice per day for one month.</description>
    <arm_group_label>Terpinen-4-ol Treatment Arm</arm_group_label>
    <other_name>T4O</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lid scrub once or twice per day for one month</description>
    <arm_group_label>Placepo Pads Contol Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic Demodex blepharitis for duration of at least 3 months.

          -  Age range: 15-80 years old.

          -  Both genders and all ethnic groups comparable with the local community.

          -  Able to understand and willing to sign a written informed consent

          -  Able and willing to cooperate with the investigational plan.

          -  Able and willing to complete all mandatory follow-up visits.

        Exclusion Criteria:

          -  Patients who are currently engaged in another clinical trial, unwilling or unable to
             give consent, to accept randomization, or to return for scheduled visits.

          -  Children under 15.

          -  Pregnant women or expecting to be pregnant during the study.

          -  Systemic immune deficient conditions such as AIDS or under systemic immunosuppressant.

          -  Concomitant use of ophthalmic topical medications (excluding non-preserved tear
             substitutes).

          -  Concomitant use of systemic antibiotics or steroids.

          -  Contact lens wear (unless discontinued for â‰¥ 30 days before randomization)

          -  Active ocular infection or allergy

          -  Unable to close eyes or uncontrolled blinking

          -  Presence of aqueous tear deficient dry eye defined by the Fluorescein Clearance Test
             as less than 3 mm wetting in 1-minute Schirmer test with anesthesia.

          -  Previous allergic reaction to TTO-containing products or cosmetic fragrance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scheffer CG Tseng, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tissue Tech Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ocular Surface Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gao YY, Di Pascuale MA, Li W, Liu DT, Baradaran-Rafii A, Elizondo A, Kawakita T, Raju VK, Tseng SC. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3089-94.</citation>
    <PMID>16123406</PMID>
  </reference>
  <reference>
    <citation>Gao YY, Di Pascuale MA, Li W, Baradaran-Rafii A, Elizondo A, Kuo CL, Raju VK, Tseng SC. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol. 2005 Nov;89(11):1468-73.</citation>
    <PMID>16234455</PMID>
  </reference>
  <reference>
    <citation>Gao YY, Di Pascuale MA, Elizondo A, Tseng SC. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea. 2007 Feb;26(2):136-43.</citation>
    <PMID>17251800</PMID>
  </reference>
  <reference>
    <citation>Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol. 2007 May;143(5):743-749. Epub 2007 Mar 21.</citation>
    <PMID>17376393</PMID>
  </reference>
  <reference>
    <citation>Kheirkhah A, Blanco G, Casas V, Tseng SC. Fluorescein dye improves microscopic evaluation and counting of demodex in blepharitis with cylindrical dandruff. Cornea. 2007 Jul;26(6):697-700.</citation>
    <PMID>17592319</PMID>
  </reference>
  <reference>
    <citation>Li J, O'Reilly N, Sheha H, Katz R, Raju VK, Kavanagh K, Tseng SC. Correlation between ocular Demodex infestation and serum immunoreactivity to Bacillus proteins in patients with Facial rosacea. Ophthalmology. 2010 May;117(5):870-877.e1. doi: 10.1016/j.ophtha.2009.09.057. Epub 2010 Jan 15.</citation>
    <PMID>20079929</PMID>
  </reference>
  <reference>
    <citation>Liang L, Safran S, Gao Y, Sheha H, Raju VK, Tseng SC. Ocular demodicosis as a potential cause of pediatric blepharoconjunctivitis. Cornea. 2010 Dec;29(12):1386-91. doi: 10.1097/ICO.0b013e3181e2eac5.</citation>
    <PMID>20847679</PMID>
  </reference>
  <reference>
    <citation>Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):505-10. doi: 10.1097/ACI.0b013e32833df9f4. Review.</citation>
    <PMID>20689407</PMID>
  </reference>
  <reference>
    <citation>Gao YY, Xu DL, Huang lJ, Wang R, Tseng SC. Treatment of ocular itching associated with ocular demodicosis by 5% tea tree oil ointment. Cornea. 2012 Jan;31(1):14-7. doi: 10.1097/ICO.0b013e31820ce56c.</citation>
    <PMID>21955627</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2012</study_first_posted>
  <results_first_submitted>November 5, 2015</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2017</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blepharitis</keyword>
  <keyword>Demodex</keyword>
  <keyword>Mites</keyword>
  <keyword>Tea Tree oil</keyword>
  <keyword>Terpinen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Terpinen-4-ol Treatment Arm</title>
          <description>8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.</description>
        </group>
        <group group_id="P2">
          <title>Placepo Pads Contol Arm</title>
          <description>9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terpinen-4-ol Treatment Arm</title>
          <description>8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.</description>
        </group>
        <group group_id="B2">
          <title>Placepo Pads Contol Arm</title>
          <description>9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="21.2"/>
                    <measurement group_id="B2" value="49" spread="18.5"/>
                    <measurement group_id="B3" value="48.8" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Number of Demodex Mites</title>
        <description>Change in mites count after treatment compared to the baseline data. If the mites' count remains zero during the last two visits, it is considered &quot;complete eradication&quot;. Patients without achieving complete eradication will be categorized as &quot;incomplete eradication&quot;.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terpinen-4-ol Treatment Arm</title>
            <description>10 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (5 patients each) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.</description>
          </group>
          <group group_id="O2">
            <title>Placepo Pads Contol Arm</title>
            <description>10 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 each) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Demodex Mites</title>
          <description>Change in mites count after treatment compared to the baseline data. If the mites' count remains zero during the last two visits, it is considered &quot;complete eradication&quot;. Patients without achieving complete eradication will be categorized as &quot;incomplete eradication&quot;.</description>
          <units>Mites</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="3.1"/>
                    <measurement group_id="O2" value="-0.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lid Margin Redness and Bulbar Conjunctival Hyperemia</title>
        <description>Lid margin redness and bulbar conjunctival hyperemia were each assessed using an ordered categorical value ranging from 0 (None) to 3 (Severe). The two scores were summed to obtain the final score, which ranges from 0 (None) to 6 (Severe).</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terpinen-4-ol Treatment Arm</title>
            <description>8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.</description>
          </group>
          <group group_id="O2">
            <title>Placepo Pads Contol Arm</title>
            <description>9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lid Margin Redness and Bulbar Conjunctival Hyperemia</title>
          <description>Lid margin redness and bulbar conjunctival hyperemia were each assessed using an ordered categorical value ranging from 0 (None) to 3 (Severe). The two scores were summed to obtain the final score, which ranges from 0 (None) to 6 (Severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.4"/>
                    <measurement group_id="O2" value="-3.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Terpinen-4-ol Treatment Arm</title>
          <description>10 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (5 patients each) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.</description>
        </group>
        <group group_id="E2">
          <title>Placepo Pads Contol Arm</title>
          <description>10 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 each) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hosam El Sheha, MD, PhD</name_or_title>
      <organization>Tissuetech Inc</organization>
      <phone>305-274-1299</phone>
      <email>hsheha@tissuetechinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

